North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

Background: Docetaxel (T; Taxotere) with capecitabine (X) is active against metastatic breast cancer (MBC); bevacizumab (BV) has demonstrated efficacy with taxanes in the first-line setting. This study was conducted to assess the safety and efficacy of TX-BV in patients with MBC. Patients and method...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Perez, E. A., Hillman, D. W., Dentchev, T., Le-Lindqwister, N. A., Geeraerts, L. H., Fitch, T. R., Liu, H., Graham, D. L., Kahanic, S. P., Gross, H. M., Patel, T. A., Palmieri, F. M., Dueck, A. C.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2813307/
https://ncbi.nlm.nih.gov/pubmed/19901014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdp512
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados